Compare AbCellera Biologics Inc (ABCL) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Domino's Pizza, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Domino's Pizza, Inc. trades at $305.54 (market cap $10.42B). The key difference: Domino's Pizza, Inc. is far larger — about 4.4× AbCellera Biologics Inc's market cap, and Domino's Pizza, Inc. pays a 2.54% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DPZ | |
|---|---|---|
Market Cap | $2.35B | $10.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $485.53 |
52-Week Low | $2.78 | $282.89 |
Enterprise Value | $1.99B | $15.32B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Domino's Pizza (DPZ) trades at $313.14, up 0.47% on the day, but remains near its 52-week low amid a bearish technical trend. The company reported mixed Q1 2026 earnings with an EPS miss of $4.13 vs. $4.27 expected, though revenue growth has been steady, reaching $4.94B in 2025. Analyst consensus is bullish with a $386.07 price target, but recent CEO transition and slowing same-store sales present near-term headwinds. Cash flow from operations remains strong at $792M in 2025, supporting dividends and buybacks.
DPZ offers value with a P/E of 17.6x and solid profitability (net margin 11.9%), but high debt levels and competitive pressures pose risks. The stock's 25% YTD decline creates a potential entry point for long-term investors, though execution under new leadership and consumer spending trends will be critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
